MARKET

GENB

GENB

Generate Biomedicines
NASDAQ
12.50
-0.02
-0.16%
Opening 09:42 10/15 EDT
OPEN
12.53
PREV CLOSE
12.52
HIGH
12.83
LOW
12.43
VOLUME
109.33K
TURNOVER
--
52 WEEK HIGH
22.67
52 WEEK LOW
11.00
MARKET CAP
1.60B
P/E (TTM)
-7.8562
1D
5D
1M
3M
1Y
5Y
1D
Generate Biomedicines: Zealand Deal For Obesity Programs May Not Be Quite What It Seems
Seeking Alpha · 20h ago
Generate Biomedicines: Zealand Partnership Expands Metabolic Pipeline as Analyst Reiterates Buy and Maintains $30 Price Target
TipRanks · 21h ago
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Benzinga · 22h ago
Piper Sandler Keeps Their Buy Rating on Generate Biomedicines, Inc. (GENB)
TipRanks · 1d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 1d ago
Biggest stock movers Wednesday: DELL, LQDA, ENVX and more
Seeking Alpha · 1d ago
Generate, Zealand in collaboration to develop drugs for obesity, metabolic diseases
Seeking Alpha · 1d ago
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
TipRanks · 1d ago
More
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Webull offers Generate Biomedicines Inc stock information, including NASDAQ: GENB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GENB stock methods without spending real money on the virtual paper trading platform.